Cardiff Oncology Q3 cash burn $7.5M; Phase 1b/2 mCRC data show 35% ORR; ONSEMBLE trial on track for Q4 activation

Cardiff Oncology, Inc.

2022-Q3 EPS reported -$0.69 revenue$258,000

Cash, equivalents, and investments $114M as of Sep 30, 2022; projected runway into 2025.
Q3 2022 net cash used in operations $7.5M vs $5.5M in Q3 2021.
Phase 1b/2 mCRC trial: ORR 35% (n=48), mPFS 9.3 months, mDoR 11.7 months.
ONSEMBLE randomized Phase 2 trial in KRAS/NRAS-mutated mCRC activation expected Q4 2022.
Bevacizumab-naïve subgroup ORR 69% and mPFS 13.5 months vs historical ~25% and 6.9 months.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Cardiff Oncology, Inc. reported financial results for the third quarter ended September 30, 2022.

Period: the third quarter ended September 30, 2022
Result: reported results

Exact text from the filing

On November 3, 2022, Cardiff Oncology, Inc. issued a press release announcing company highlights and financial results for the third quarter ended September 30, 2022.

View on SEC.gov

44 earnings releases filed in the last 30 days. Browse all earnings releases →

Cardiff Oncology, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-22-028200

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.